Impact of triple Combination Therapy for People with CF with Sinusitis

Trial Objective

Impact of triple Combination Therapy for People with CF with SinusitisThis observational study will assess the impact of a new triple combination CFTR modulator therapy on chronic sinusitis in adults with cystic fibrosis. This triple combination therapy is made up of the drugs, ivacaftor, tezacaftor and elexacaftor, and in previous studies has been shown to improve lung function and sweat chloride.

Researchers are trying to determine if this new triple combination therapy can also improve computed tomography sinus CT scan findings, sense of smell and quality of life for people with CF with chronic sinusitis.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults with chronic sinusitis and cystic fibrosis who are prescribed elexacaftor-tezacaftor-ivacaftor by their clinic doctor.

Age: 18-80    Gender: Any Gender

Estimated Time Commitment

6 months

This study will include a baseline visit lasting 2-3 hours at the beginning of the study and a follow up appointment lasting approximately 2 hours 6 months into the study. CT scans will be performed at both the baseline and follow-up visits. Participants are expected to receive monthly phone calls and take electronic surveys between the two appointments.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Connor Balkissoon

Connor Balkissoon

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Cystic Fibrosis Foundation and the Marshall and Margherite McComb Foundation

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at